je.st
news
Home
› MetaStat Announces Commencement Of Its Comprehensive Drug Development Program With Significant New Hires And Research Facility Opening
MetaStat Announces Commencement Of Its Comprehensive Drug Development Program With Significant New Hires And Research Facility Opening
2013-10-02 06:24:58| drugdiscoveryonline News Articles
MetaStat Inc., a life science company focused on understanding and treating systemic metastasis, recently announced that it has commenced its comprehensive drug development program with the hiring of Elizabeth Buck, Ph.D. and Matthew O'Connor, both formerly of OSI Pharmaceuticals, Inc. (acquired by Astellas Pharma, Inc.), along with the opening of its new drug discovery research facility located in Stony Brook, NY. Both Dr. Buck and Mr. O'Connor will work closely and in collaboration with Dr. David Epstein, MetaStat's Head of Drug Development and former Chief Scientific Officer of OSI Pharmaceuticals
Tags: research
development
program
significant
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||